Rhythm Biosciences
Rhythm Biosciences is an Australian medtech company that develops blood-based cancer diagnostics, including the ColoSTAT colorectal cancer test and the geneType polygenic risk score portfolio, serving clinicians, health systems, and pathology networks across Australia, the US, the UK, and Southeast Asia.
- Company typePublic
- Founded2019
- HeadquartersMelbourne, Australia
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Rhythm Biosciences does
Rhythm Biosciences Limited (ASX:RHY) is an Australian medical diagnostics technology company that develops and commercializes blood-based tests for the prediction and early detection of cancer. The company operates a dual-product portfolio: ColoSTAT®, a proprietary multiplex immunoassay blood test designed to detect colorectal cancer in symptomatic patients and described as Australia's first such test, and geneType™, a portfolio of personalized predictive tests that combine polygenic risk scores (PRS) with clinical and family history data to forecast individual risk across six cancer types. The geneType portfolio includes the Multi Risk Test (MRT) and the Hereditary Breast and Ovarian Cancer (HBOC) test, the latter of which has received FDA clearance for the US market. The platform rests on a second-generation multiplex alpha immunoassay chemistry for ColoSTAT and a patented PRS framework for geneType, supported by 25 granted patents (plus 9 pending), NATA ISO15189:2022-accredited laboratory operations, and ISO 13485 medical device certification.
The business model combines one-time product revenue from ColoSTAT kit sales with recurring testing services revenue from geneType laboratory operations, supplemented by Australian R&D tax incentives and non-dilutive funding facilities (e.g., an Endpoints Capital loan tranche). Commercialization is executed through a hybrid go-to-market: direct enterprise sales for ColoSTAT paired with channel partnerships — most notably a CancerIQ platform integration reaching 60-65 US health systems, a 4Cyte Pathology collection agreement in Australia, an AGRF partnership for laboratory scale-up, and regional distribution agreements for the UK and Southeast Asia. The company serves three primary segments: healthcare providers and clinicians ordering the tests, large health systems and hospital networks seeking population-level screening tools, and at-risk individuals seeking personalized risk assessment.
Rhythm remains in early commercial launch phase. Its flagship ColoSTAT product commenced commercialization in December 2025 following ISO15189:2022 accreditation, with the first clinical test sale recorded in March 2026. The geneType portfolio was added through an acquisition completed in December 2024, with first commercial sales recorded shortly thereafter and international expansion into Southeast Asia commencing in early 2026. The company maintains wholly-owned subsidiaries in the US (established July 2021) and the UK (established July 2023) to support multi-region growth.
Rhythm Biosciences firmographics
Firmographics- Name
- Rhythm Biosciences
- Legal name
- Rhythm Biosciences
- Website
- https://rhythmbio.com
- Company type
- Public
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Rhythm Biosciences is an Australian medtech company that develops blood-based cancer diagnostics, including the ColoSTAT colorectal cancer test and the geneType polygenic risk score portfolio, serving clinicians, health systems, and pathology networks across Australia, the US, the UK, and Southeast Asia.
- Ownership category
- akta.pro rank
Rhythm Biosciences industry classification
Industry- Product category
- Cancer Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Scientific Research and Development Services (5417)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)
- akta.pro secondary industries
- Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE), Clinical Research & Trial Central Laboratories (HLAFAMAL)
Keywords
Where Rhythm Biosciences is headquartered
LocationHeadquarters
- HQ city
- Melbourne
- HQ country
- Australia
- HQ region
- Oceania
Offices1 record
Markets served
Rhythm Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- ColoSTAT Product Sales: Revenue from sale of ColoSTAT blood test kits for colorectal cancer detection in symptomatic patients. Commercial manufacturing agreement secured for kit production.
- geneType Laboratory Testing Services: Revenue from geneType cancer risk assessment testing services, including polygenic risk score tests for multiple cancer types. Laboratory operations NATA ISO15189 certified.
- Non-Dilutive Funding: Company receives R&D tax incentives from Australian government and non-dilutive funding arrangements such as the Endpoints Capital loan facility.
Go-to-market motion2 records
Distribution channels5 records
Marketing channels5 records
Rhythm Biosciences product offering
Product offeringCore offering
Rhythm Biosciences develops and commercialises proprietary blood-based diagnostic tests for cancer detection and risk assessment. Its flagship product ColoSTAT is a blood test for colorectal cancer detection in symptomatic patients, and the geneType portfolio combines genomic and clinical data into polygenic risk score tests covering multiple cancer types. The company manufactures test kits, operates NATA ISO15189-certified laboratories, and distributes through pathology networks, health system platforms, and international partners.
Product overview
Rhythm Biosciences operates a dual-product portfolio focused on cancer diagnostics. The company's flagship products are ColoSTAT® (a blood-based test for colorectal cancer detection in symptomatic patients) and geneType™ (a world-leading personalised predictive test portfolio combining genomic and clinical information to assess cancer risk across multiple cancer types). geneType™ includes the Multi Risk Test (MRT) that assesses multiple conditions simultaneously, and the Hereditary Breast and Ovarian Cancer (HBOC) test. The company is expanding its proprietary immunoassay technology platform to develop diagnostic tests for additional cancer types including lung, gastric, and breast cancer.
Differentiator
Problem solved
Functional benefit
Brands
- ColoSTAT: Blood-based test for the early detection of colorectal cancer in symptomatic patients.
- geneType
Products and services
- ColoSTAT® Australia's first blood-based test for detection of colorectal (bowel) cancer in symptomatic patients. A proprietary multiplex immunoassay designed to support risk stratification and help clinicians determine which patients may benefit from further investigation such as colonoscopy.
- geneType™ Platform Portfolio of personalised predictive tests combining genomic and clinical information, including family history, to forecast an individual's risk of developing cancer. Provides 5-year and lifetime cancer risk estimates across six cancer types.
- geneType™ Multi Risk Test (MRT) Sub-product within the geneType portfolio that assesses multiple cancer conditions simultaneously using polygenic risk scores combined with clinical and family history data. 79.5% of tests deliver novel health insights previously unknown to patients.
- geneType™ Hereditary Breast and Ovarian Cancer (HBOC) Test Comprehensive screening tool for hereditary breast and ovarian cancer risk assessment, currently available in the US market following FDA clearance.
Quantifiable outcome
- 79.5% of geneType Multi Risk Tests provide novel health insights previously unknown to patients
- +2 more outcomes
Companies that use Rhythm Biosciences
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
Rhythm Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Rhythm Biosciences partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered minor and core.
- Southeast Asian Distribution PartnerminorRhythm Biosciences executed a distribution agreement for geneType in the Southeast Asian market, enabling geographic expansion across the region.
- 4Cyte PathologycoreRhythm Biosciences entered into a ColoSTAT services agreement with 4Cyte Pathology for specimen collection and testing services. 4Cyte Pathology operates an expanding network of collection sites supporting the commercial rollout of ColoSTAT across Australia.
- AGRF (Australian Genome Research Facility)coreRhythm Biosciences established a strategic partnership with AGRF to accelerate commercial scale-up of the geneType service. AGRF provides laboratory and genomic services supporting expanded testing capacity and operational scaling.
- CancerIQcoreCancerIQ is a US digital healthcare platform that integrated Rhythm Biosciences' geneType cancer risk assessment test into its platform. This partnership expands diagnostic options across CancerIQ's network of over 60 health systems in the United States, enhancing risk prediction by incorporating polygenic risk scores and clinical data for six cancer types. The integration enables healthcare providers to order tests more efficiently through established clinical workflows, expanding patient access to predictive cancer diagnostics.
- datmaminordatma and Rhythm Biosciences announced an exploratory collaboration to evaluate how datma's federated real-world data platform (datma.FED) could support Rhythm's cancer risk prediction technology development. The collaboration aims to assess the contribution of longitudinal, de-identified clinical data to support clinical utility and health economic modelling of Rhythm's geneType risk assessment portfolio, potentially enhancing commercialization and clinical validation of genomic-integrated cancer diagnostics.
- Catch BiominorRhythm Biosciences entered a US marketing partnership with Catch Bio to support commercial adoption and marketing efforts in the United States market.
- Memorial Sloan Kettering (MSK)minorCollaboration with Memorial Sloan Kettering Cancer Center, a world-renowned cancer research and treatment institution, for cancer diagnostics development.
- LINK Medical SolutionsminorUK strategic partnership with LINK Medical Solutions for UK market entry and commercialization support. LINK Medical Solutions provides medical device commercialization expertise in the UK market.
Scale indicators9 records
Recent moves8 records
Expansion highlights6 records
Rhythm Biosciences competitors and assessment
Company assessmentOthers
Direct peers
- Guardant Health: US liquid-biopsy company offering blood-based cancer screening (Shield for CRC) and comprehensive genomic profiling. Direct blood-based CRC competitor and overlapping oncology liquid-biopsy peer with substantially larger capital base.
- Exact Sciences: US-listed developer of Cologuard, the leading non-invasive stool-DNA test for colorectal cancer screening. Direct competitor in non-invasive CRC detection; however, blood-based vs stool-based modalities differ and Exact Sciences has substantially greater scale and US reimbursement coverage.
Broad incumbents
- Natera: US cell-free DNA testing company with oncology screening (Signatera MRD) and reproductive health offerings. Comparable as a blood-based cancer diagnostics peer with established US commercial infrastructure, though core franchise is MRD rather than screening.
- Myriad Genetics: US established genetic testing company with hereditary cancer (BRACAnalysis) and other risk-prediction products. Direct comparable on the geneType-style hereditary cancer and polygenic risk offering, with established US clinical channel.
Emerging players
- Freenome: Privately held US multiomics blood-based cancer screening company focused on CRC with an emerging pipeline into other cancers. Closely comparable in modality and product category but at a different development and capital stage.
- Personalis: US cancer genomics company focused on minimal residual disease detection and immunotherapy selection. Comparable as a clinical genomics peer operating at similar scale, though its core focus is post-diagnosis rather than screening or risk prediction.
- Universal Diagnostics: Privately held developer of blood-based colorectal cancer screening tests. Closely comparable modality (blood-based CRC detection) and competitor in the same clinical category.
Regional players
- Sonic Healthcare: ASX-listed global pathology and radiology provider with major Australian clinical laboratory operations. Comparable Australian-region pathology infrastructure and a likely channel partner or competitive constraint for ColoSTAT specimen logistics.
- Healius (formerly Primary Health Care): Australian operator of pathology and diagnostic services including QML, Dorevitch and Laverty pathology networks. Comparable as a regional Australian diagnostics and pathology services incumbent and potential distribution channel for ColoSTAT.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Rhythm Biosciences social profiles
Digital presenceRhythm Biosciences compliance and trust
Trust signalCompliance4 records
Rhythm Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Rhythm Biosciences leadership team
Management profileNumber of profiles
Profiles7 records
Rhythm Biosciences subsidiaries and ownership
Company hierarchySubsidiaries2 records
Rhythm Biosciences funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Rhythm Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Rhythm Biosciences
What does Rhythm Biosciences do?
Rhythm Biosciences develops and commercialises proprietary blood-based diagnostic tests for cancer detection and risk assessment. Its flagship product ColoSTAT is a blood test for colorectal cancer detection in symptomatic patients, and the geneType portfolio combines genomic and clinical data into polygenic risk score tests covering multiple cancer types. The company manufactures test kits, operates NATA ISO15189-certified laboratories, and distributes through pathology networks, health system platforms, and international partners.
Is Rhythm Biosciences a public or private company?
Rhythm Biosciences is a public company. It is classified as public and is currently operating.
When was Rhythm Biosciences founded?
Rhythm Biosciences was founded in 2019. It employs 11 to 50 people.
Where is Rhythm Biosciences based?
Rhythm Biosciences is headquartered in Melbourne, Australia, in the Oceania region.
How does Rhythm Biosciences make money?
Three revenue lines are on record. ColoSTAT Product Sales are the primary driver. The others are geneType Laboratory Testing Services and non-Dilutive Funding.
Who are Rhythm Biosciences's main competitors?
Genomic Health (Exact Sciences subsidiary) is listed as an others. Direct peers are Guardant Health and Exact Sciences. Broad incumbents are Natera and Myriad Genetics. Emerging players are Freenome, Personalis and Universal Diagnostics. Regional players are Sonic Healthcare and Healius (formerly Primary Health Care).
Does Rhythm Biosciences have an API?
No public API is recorded for Rhythm Biosciences.
What industry is Rhythm Biosciences in?
Rhythm Biosciences's product category is Cancer Diagnostics. Its primary akta.pro industry code is HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays), with a secondary code of HLAAAMAJ, Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics). Its NAICS code is 325413 and its SIC code is 2835.